<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999933</url>
  </required_header>
  <id_info>
    <org_study_id>XJFL-201309-CCPOSTOP</org_study_id>
    <nct_id>NCT01999933</nct_id>
  </id_info>
  <brief_title>Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer</brief_title>
  <official_title>Clinical Study on Docetaxel Plus Cisplatin(TP) Regimen Combined With Postoperative Radiotherapy for Stage Ia2- IIb Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mei Shi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Air Force Military Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a randomized, control, phase II/III study of early stage (FIGO Ia2-IIb)&#xD;
      cervical cancer after radical hysterectomy in Northwest China treated with radiotherapy or&#xD;
      concurrent chemoradiotherapy based on the surgical-pathological risk factors. All the&#xD;
      patients received whole pelvis radiation and were divided into three groups according to&#xD;
      adjuvant chemotherapy: concurrent chemotherapy with cisplatin weekly (40mg/m2) , concurrent&#xD;
      chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), or concurrent and adjuvant&#xD;
      chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2). The effectiveness, and side&#xD;
      effects will be evaluated according to Standard WHO response criteria, and NCI common&#xD;
      toxicity criteria for adverse events(NCI-CTC-AE) V3.0.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To the cervical cancer patient who accepted radical hysterectomy, whether the adjuvant&#xD;
      therapy should be received or the method of adjuvant therapy are determined by the&#xD;
      postoperative pathology. In the traditional opinion, the postoperative risk factors were&#xD;
      divided into two groups: intermediate risk factors, including large tumor size, deep stromal&#xD;
      invasion and lymphovascular space invasion, and high risk factors, including non-squamous&#xD;
      cell carcinoma, marginal positive, parametric invasion and pelvic lymph node(LN) metastasis.&#xD;
      Patients with intermediate risk factors should accepted adjuvant radiotherapy only and who&#xD;
      with high risk factors should received adjuvant concurrent chemoradiotherapy. Cisplatin&#xD;
      weekly(40mg/m2) was the standard regimen of concurrent chemotherapy. However, we&#xD;
      retrospectively analyzed 801 cervical cancer patients with postoperative radiotherapy and&#xD;
      found that distant metastasis was the main cause of current treatment failure(84.5%), which&#xD;
      suggested the current regimen of chemotherapy was insufficient and might be strengthened in&#xD;
      future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5-years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic adverse events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Toxicity Due to Radiotherapy</condition>
  <arm_group>
    <arm_group_label>CCRT with cisplatin(DDP) weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCRT with TP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concurrent TP tri-weekly, docetaxel plus cisplatin tri-weekly (75mg/m2), begin with radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>concurrent and adjuvant TP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cycles of concurrent TP, docetaxel plus cisplatin tri-weekly (75mg/m2),begin with radiation; and 4 cycles of adjuvant TP, the same regimen, after radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.</description>
    <arm_group_label>CCRT with TP</arm_group_label>
    <arm_group_label>CCRT with cisplatin(DDP) weekly</arm_group_label>
    <arm_group_label>concurrent and adjuvant TP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin（DDP） weekly</intervention_name>
    <description>concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation</description>
    <arm_group_label>CCRT with cisplatin(DDP) weekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel plus cisplatin</intervention_name>
    <description>concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation</description>
    <arm_group_label>CCRT with TP</arm_group_label>
    <arm_group_label>concurrent and adjuvant TP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel plus cisplatin</intervention_name>
    <description>adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation</description>
    <arm_group_label>concurrent and adjuvant TP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 Years to 70 Years&#xD;
&#xD;
          -  Histologically proven cervical cancer, FIGO stage Ia2-IIb,and no previous chemotherapy&#xD;
             and radiotherapy&#xD;
&#xD;
          -  Accepted radical hysterectomy 3-4 weeks before&#xD;
&#xD;
          -  Karnofsky score &gt;70&#xD;
&#xD;
          -  Postoperative pathology with following risk factors: Non-squamous cell carcinoma, deep&#xD;
             stromal invasion, lymphovascular space invasion, marginal positive, parametria&#xD;
             invasion, large tumor size (tumor diameter&gt;4cm) or pelvic LN metastasis. Patients with&#xD;
             pelvic LN metastasis and combination of any two or more risk factors mentioned above&#xD;
             were included.&#xD;
&#xD;
          -  Examination results showed no radiation or chemotherapy contraindication&#xD;
&#xD;
          -  Willing to accept treatment&#xD;
&#xD;
          -  Ability to comply with trial requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Postoperative residual&#xD;
&#xD;
          -  Postoperative recurrence or metastasis&#xD;
&#xD;
          -  Without lymph node dissection&#xD;
&#xD;
          -  Postoperative pathology showed aortic lymph node metastasis&#xD;
&#xD;
          -  Examination results showed radiotherapy contraindications&#xD;
&#xD;
          -  No indications for radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mei Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>department of radiation oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei Shi, MD.PhD</last_name>
    <phone>+86-029-84775425</phone>
    <email>mshifmmu@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Shi, MD</last_name>
      <phone>+86-029-84775425</phone>
      <email>mshifmmu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mei Shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-Chun Wei, M.D.,Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Air Force Military Medical University, China</investigator_affiliation>
    <investigator_full_name>Mei Shi</investigator_full_name>
    <investigator_title>Director and Professor of Department of Radiation Oncology, Xijing Hospital</investigator_title>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>postoperative risk factor</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

